| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,005 |
99,487 |
197,241 |
249,694 |
| Total Sell Value |
$596,362 |
$4,824,734 |
$8,130,065 |
$10,494,293 |
| Total People Sold |
2 |
8 |
9 |
12 |
| Total Sell Transactions |
3 |
12 |
19 |
35 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sharp Shalini |
CFO & Executive Vice President |
• – – |
2018-03-01 |
4 |
D |
$48.43 |
$19,227 |
D/D |
(397) |
62,113 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
62,510 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2018-03-01 |
4 |
D |
$48.43 |
$53,951 |
D/D |
(1,114) |
448,955 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
19,500 |
450,069 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2018-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
18,000 |
|
- |
|
| Aliski William |
Director |
– • – |
2018-01-23 |
4 |
OE |
$21.00 |
$241,500 |
D/D |
11,500 |
73,360 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2017-08-28 |
4 |
B |
$52.40 |
$393,922 |
I/I |
7,500 |
2,559,741 |
2.66 |
- |
|
| Dallas Jayson Donald Alexander |
EVP & Chief Commercial Officer |
• – – |
2017-08-03 |
4 |
D |
$62.59 |
$58,835 |
D/D |
(940) |
16,107 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2017-07-16 |
4 |
D |
$64.36 |
$45,374 |
D/D |
(705) |
11,883 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
3,750 |
|
- |
|
| Narachi Michael |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
3,750 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
15,069 |
|
- |
|
| Siegall Clay B |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
3,750 |
|
- |
|
| Dunsire Deborah |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
1,875 |
|
- |
|
| Ekman Lars |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
3,750 |
|
- |
|
| Aliski William |
Director |
– • – |
2017-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
61,860 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2017-06-20 |
4 |
D |
$63.38 |
$44,683 |
D/D |
(705) |
8,795 |
|
- |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2017-06-01 |
4 |
D |
$56.61 |
$15,964 |
D/D |
(282) |
10,939 |
|
- |
|
| Dallas Jayson Donald Alexander |
EVP & Chief Commercial Officer |
• – – |
2017-06-01 |
4 |
D |
$56.61 |
$18,115 |
D/D |
(320) |
17,047 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2017-06-01 |
4 |
D |
$56.61 |
$21,285 |
D/D |
(376) |
76,228 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2017-06-01 |
4 |
D |
$56.61 |
$56,950 |
D/D |
(1,006) |
430,569 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2017-06-01 |
4 |
D |
$56.61 |
$15,964 |
D/D |
(282) |
12,588 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2017-06-01 |
4 |
D |
$56.61 |
$21,285 |
D/D |
(376) |
55,470 |
|
- |
|
| Huizenga Theodore Alan |
VP, Controller and PAO |
• – – |
2017-05-26 |
4 |
S |
$57.46 |
$27,581 |
D/D |
(480) |
9,366 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2017-05-21 |
4 |
D |
$57.47 |
$61,608 |
D/D |
(1,072) |
431,575 |
|
- |
|
628 Records found
|
|
Page 19 of 26 |
|
|
0.37 (0.89%) 
